Reference Laboratories

Berlin, Germany

Reference Laboratories

Berlin, Germany
SEARCH FILTERS
Time filter
Source Type

MIAMI, May 18, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that data from a prospective study conducted at Veteran Affairs (VA) hospitals confirming the 4Kscore test’s ability to accurately predict aggressive prostate cancer were presented in a podium presentation on May 16, 2017 at the 112th American Urological Association (AUA) Annual Meeting in Boston.  The study entitled, “An Independent, Multi-Institutional, Prospective study in the Veterans Affairs Health System confirms the 4Kscore accurately predicts aggressive prostate cancer,” was presented by Sanoj Punnen, M.D., Assistant Professor of Urologic Oncology at the Miller School of Medicine, Department of Urology at the University of Miami in Miami, Florida. The study is the second U.S. prospective clinical study to establish the clinical validity of the 4Kscore test to predict the presence of aggressive prostate cancer prior to performing a prostate biopsy. The VA study was conducted at eight VA hospitals across the United States. A total of 366 men were enrolled in the study, and 208 (56%) of the participants were African American. Of all cancers diagnosed among African American men, prostate cancer is the most common (31% of all cancers), and African American men have a twofold greater risk of prostate cancer mortality compared to non-Hispanic whites.1 Overall, the 4Kscore demonstrated a high degree of accuracy for predicting the presence of aggressive (Gleason score 7 and higher) prostate cancer with an area under the receiver operator curve (AUC) of 0.81, significantly better than PSA alone or a clinical model based on PSA. Importantly, there was an equally high ability of the 4Kscore to discern aggressive disease in the African American men compared with the non-African American men (AUC = 0.80 v. 0.84, p = 0.32). The calibration and decision curve analysis were also consistent with the performance shown in the first U.S. validation study. “The VA study confirms the 4Kscore’s accuracy in predicting a man’s risk of having aggressive prostate cancer and showed that it is an equally effective and vital clinical test for African American men, who have the highest rates of prostate cancer mortality,” said Phillip Frost, M.D., Chairman and CEO of OPKO Health. “These positive results add to our growing body of clinical evidence that demonstrate 4Kscore’s utility to accurately identify the risk of aggressive prostate cancer. Moreover, these data validate the clinical value of the 4Kscore test in a VA setting and show it to be identical to the performance previously shown in community and academic sites across the U.S. and Europe.” According to the Prostate Cancer Foundation,2 “every 3.3 minutes a man is diagnosed with prostate cancer, and millions of men and their families are fighting the disease globally. In the United States, prostate cancer affects 1 in 8 men, making it the most common non-skin cancer in America. This means that a non-smoking man is more likely to develop prostate cancer than he is to develop colon, bladder, melanoma, lymphoma, and kidney cancers combined. In 2017 alone, it is estimated that more than 161,000 men will be diagnosed with prostate cancer, and more than 27,000 will die from the disease. A man of African descent is 73% more likely to develop prostate cancer than a Caucasian man, and more than twice as likely to die from the disease.” The 4Kscore is the only blood test that accurately identifies risk for aggressive prostate cancer. The 4Kscore measures the blood plasma levels of four different prostate-derived kallikrein proteins: Total PSA, Free PSA, Intact PSA and human kallikrein-related peptidase 2 (hK2). These biomarkers are combined with a patient's age, digital rectal exam (DRE) status (nodule / no nodule), and prior negative biopsy status (yes / no) using a proprietary algorithm that calculates the risk (probability) of finding a Gleason Score 7 or higher prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore test is based on over a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions. The 4Kscore test provides individualized risk for the presence of aggressive prostate cancer and adds new information to the patient-physician shared decision making discussion. The 4Kscore test is included in the 2016 National Comprehensive Cancer Network and 2016 European Association of Urology Prostate Cancer Guidelines. OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic Hypertrophy) , OPK88002, a NK-1 antagonist to treat pruritus ( itching) in dialysis patients, and OPK88001, a proprietary oligonucleotide to treat Dravet Syndrome. In addition, the Company is advancing its CTP technology, which includes a long acting hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long acting Factor VIIa drug for hemophilia in phase 2a. OPKO also has production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com. This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the clinical utility for the 4Kscore test, its ability to accurately predict aggressive prostate cancer in men generally and in the African American population, the expected benefits of our 4Kscore test, whether clinical trial results are indicative of the 4Kscore test's ability to predict aggressive prostate cancer, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


MIAMI, May 18, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that data from a prospective study conducted at Veteran Affairs (VA) hospitals confirming the 4Kscore test’s ability to accurately predict aggressive prostate cancer were presented in a podium presentation on May 16, 2017 at the 112th American Urological Association (AUA) Annual Meeting in Boston.  The study entitled, “An Independent, Multi-Institutional, Prospective study in the Veterans Affairs Health System confirms the 4Kscore accurately predicts aggressive prostate cancer,” was presented by Sanoj Punnen, M.D., Assistant Professor of Urologic Oncology at the Miller School of Medicine, Department of Urology at the University of Miami in Miami, Florida. The study is the second U.S. prospective clinical study to establish the clinical validity of the 4Kscore test to predict the presence of aggressive prostate cancer prior to performing a prostate biopsy. The VA study was conducted at eight VA hospitals across the United States. A total of 366 men were enrolled in the study, and 208 (56%) of the participants were African American. Of all cancers diagnosed among African American men, prostate cancer is the most common (31% of all cancers), and African American men have a twofold greater risk of prostate cancer mortality compared to non-Hispanic whites.1 Overall, the 4Kscore demonstrated a high degree of accuracy for predicting the presence of aggressive (Gleason score 7 and higher) prostate cancer with an area under the receiver operator curve (AUC) of 0.81, significantly better than PSA alone or a clinical model based on PSA. Importantly, there was an equally high ability of the 4Kscore to discern aggressive disease in the African American men compared with the non-African American men (AUC = 0.80 v. 0.84, p = 0.32). The calibration and decision curve analysis were also consistent with the performance shown in the first U.S. validation study. “The VA study confirms the 4Kscore’s accuracy in predicting a man’s risk of having aggressive prostate cancer and showed that it is an equally effective and vital clinical test for African American men, who have the highest rates of prostate cancer mortality,” said Phillip Frost, M.D., Chairman and CEO of OPKO Health. “These positive results add to our growing body of clinical evidence that demonstrate 4Kscore’s utility to accurately identify the risk of aggressive prostate cancer. Moreover, these data validate the clinical value of the 4Kscore test in a VA setting and show it to be identical to the performance previously shown in community and academic sites across the U.S. and Europe.” According to the Prostate Cancer Foundation,2 “every 3.3 minutes a man is diagnosed with prostate cancer, and millions of men and their families are fighting the disease globally. In the United States, prostate cancer affects 1 in 8 men, making it the most common non-skin cancer in America. This means that a non-smoking man is more likely to develop prostate cancer than he is to develop colon, bladder, melanoma, lymphoma, and kidney cancers combined. In 2017 alone, it is estimated that more than 161,000 men will be diagnosed with prostate cancer, and more than 27,000 will die from the disease. A man of African descent is 73% more likely to develop prostate cancer than a Caucasian man, and more than twice as likely to die from the disease.” The 4Kscore is the only blood test that accurately identifies risk for aggressive prostate cancer. The 4Kscore measures the blood plasma levels of four different prostate-derived kallikrein proteins: Total PSA, Free PSA, Intact PSA and human kallikrein-related peptidase 2 (hK2). These biomarkers are combined with a patient's age, digital rectal exam (DRE) status (nodule / no nodule), and prior negative biopsy status (yes / no) using a proprietary algorithm that calculates the risk (probability) of finding a Gleason Score 7 or higher prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore test is based on over a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions. The 4Kscore test provides individualized risk for the presence of aggressive prostate cancer and adds new information to the patient-physician shared decision making discussion. The 4Kscore test is included in the 2016 National Comprehensive Cancer Network and 2016 European Association of Urology Prostate Cancer Guidelines. OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic Hypertrophy) , OPK88002, a NK-1 antagonist to treat pruritus ( itching) in dialysis patients, and OPK88001, a proprietary oligonucleotide to treat Dravet Syndrome. In addition, the Company is advancing its CTP technology, which includes a long acting hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long acting Factor VIIa drug for hemophilia in phase 2a. OPKO also has production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com. This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the clinical utility for the 4Kscore test, its ability to accurately predict aggressive prostate cancer in men generally and in the African American population, the expected benefits of our 4Kscore test, whether clinical trial results are indicative of the 4Kscore test's ability to predict aggressive prostate cancer, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


MIAMI, May 15, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq:OPK) announces that multiple podium and poster presentations highlighting the Company’s 4Kscore test will be presented at the 112th American Urological Association (AUA) Annual Meeting taking place from May 12-16, 2017 in Boston. The following podium and poster presentations highlighting the 4Kscore test will take place in Room 162 of the Boston Convention and Exhibition Center: To learn more about the Company’s 4Kscore test and Claros 1 Point-of-Care system, visit the OPKO Health Booth #904 in the Exhibit Hall. About the 4Kscore™ Test The 4Kscore is the only blood test that accurately identifies risk for aggressive prostate cancer. The 4Kscore measures the blood plasma levels of four different prostate-derived kallikrein proteins: Total PSA, Free PSA, Intact PSA and human kallikrein-related peptidase 2 (hK2). These biomarkers are combined with a patient's age, digital rectal exam (DRE) status (nodule / no nodule), and prior negative biopsy status (yes / no) using a proprietary algorithm that calculates the risk (probability) of finding a Gleason Score 7 or higher prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore test is based on over a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions. The 4Kscore test provides individualized risk for the presence of aggressive prostate cancer and adds new information to the patient-physician shared decision making discussion. The 4Kscore test is included in the 2016 National Comprehensive Cancer Network and 2016 European Association of Urology Prostate Cancer Guidelines. About OPKO Health, Inc.   OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, OPK88004, an androgen receptor modulator for androgen deficiency indications, OPK88002, a NK-1 inhibitor to treat pruritus (severe itching) in dialysis patients, and OPK88001, a proprietary oligonucleotide to treat Dravet Syndrome. In addition, the Company is advancing its CTP technology, which includes a long-acting hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia in phase 2a.  OPKO also has production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected clinical utility and financial performance and expectations regarding our 4Kscore test  and the expected benefits of our 4Kscore test, whether clinical trial results are indicative of the 4Kscore test’s ability to predict aggressive prostate cancer,  as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


News Article | May 8, 2017
Site: globenewswire.com

MIAMI, May 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months ended March 31, 2017, after the close of the U.S. financial markets on Tuesday, May 9, 2017. OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, May 9, 2017. For those unable to participate in the live conference call or webcast, a replay will be available beginning May 9, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 17226044. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.


News Article | May 1, 2017
Site: www.marketwired.com

ALBUQUERQUE, NM--(Marketwired - May 01, 2017) - TriCore Reference Laboratories' CEO Khosrow Shotorbani will be a keynote speaker at this week's Executive War College on Laboratory and Pathology Management in New Orleans, Louisiana. The international conference showcases innovations by leading laboratory organizations worldwide and helps laboratory administrators and pathologists learn practical methods for improving the performance and financial success of their laboratories. Shotorbani will speak at a general session on Tuesday, May 2, on the future of clinical lab services and opportunities for labs to prosper in the future state of healthcare. Shotorbani will provide insights on how TriCore is developing and providing enriched lab services that add new value for physicians, payers and, ultimately, patients in New Mexico. Shotorbani said, "TriCore and New Mexico are serving as an incubator for the future clinical laboratory business model, reshaping the way healthcare is delivered. I am proud to share our story on the international stage." TriCore representatives, Shotorbani as well as VP of IT, Aron Seidman, and members of the Enterprise Clinical Solutions team, Kathleen Swanson and Monique Dodd, will also present in a full-day, post-conference workshop on Clinical Lab 2.0 as part of Project Santa Fe. Project Santa Fe includes leaders from five clinical laboratory operations across the country: Henry Ford Health System, Geisinger Health System, Kaiser Permanente Northern California Health Systems, Northwell Health Laboratories, and TriCore Reference Laboratories. The coalition was established both to provide thought leadership and to help develop the evidence base for the valuation of clinical laboratory services in the next era of American healthcare. TriCore Reference Laboratories is a clinical reference laboratory founded and headquartered in Albuquerque, NM that provides over 1,700 full-service, state-of-the-art laboratory tests to health care professionals and their patients. TriCore also provides investigational services including FDA-regulated clinical trials, IRB-approved studies, and instrument testing. For more information, visit tricore.org. For more information on the Executive War College visit executivewarcollege.com


News Article | April 13, 2017
Site: globenewswire.com

ALBUQUERQUE, N.M., April 13, 2017 (GLOBE NEWSWIRE) -- The Albuquerque March of Dimes has named TriCore Reference Laboratories' Chief Administration Officer, Dr. Nick Dayan, as the 2017/2018 Chair of the Albuquerque March for Babies. TriCore is also the signature sponsor of this year's event. Dr. Dayan said of being chosen the Chair of the event, "I am so honored to be named the Chair of this marvelous event. By supporting the March for Babies program, we as a community have the ability to affect our newborns for a lifetime." The March for Babies will be held on Saturday, May 6, 2017 at Johnson Field on the UNM Campus. Registration will be at 10:00AM and the walk starts at 11:30AM. Please go to: bit.ly/marchforbabiesABQ for more information or to register to be a participant. Nearly 4 million babies are born annually in the US. All babies, whether they are born early or on time benefit from advances in prenatal and postpartum care made possible by the March of Dimes. Since 1970, March for Babies has been the biggest fundraiser for the March of Dimes in Albuquerque – last year's event raised $169,000 with the donations going to support the March of Dimes local efforts as well as support the five national Prematurity Research Centers. Lori Medik, Executive Director of Market Development for the March of Dimes, stated, "March for Babies is an incredible community event that allows us to focus attention on prematurity, birth defects, and infant mortality. Annually, in New Mexico 25,800 babies are born. Of these babies, 2,448 are born preterm, 782 are born with a birth defect, and 139 die before reaching their first birthday. While not everyone has a direct mission connection, everyone is affected by prematurity, birth defects, and infant mortality. Preterm birth alones costs our state $126 million a year, approximately $26 billion nationally. We care about all babies and March for Babies is an opportunity for each of us to make a difference." About March of Dimes The March of Dimes is the leading nonprofit organization for pregnancy and baby health. For more than 75 years, moms and babies have benefited from March of Dimes research, education, vaccines, and breakthroughs. About TriCore Reference Laboratories TriCore Reference Laboratories is a clinical reference laboratory providing a complete range of services to health care professionals across the Southwest as well as pathology consultation services to clinicians across the country. For more information, visit www.tricore.org


What's the Size of the Clinical Laboratory Market in Several Country Markets? Global Laboratory Market: by-Country Market Analysis (U.S., China, Japan, Germany, France, Spain, Italy, Brazil, EMEA and others) provides an overview of the clinical laboratory industry and the trends driving growth. Market data presented include the following: Internationally, the clinical laboratory market is growing. Clinical Laboratory Services Market presents information as a global focused market report. Key regions discussed include Northern America; Europe, Middle East, and Africa (EMEA); Asia Pacific; and Latin America. Datasets provided include the following: - Estimated U.S. Laboratory Service Revenues and Market Share of Leading Clinical Laboratory Providers, 2016 - Estimated U.S. Laboratory Service Revenues for Leading Clinical Laboratory Providers, 2010 vs. 2016 Trends and Issues discussed in this report are inclusive of population statistics,  disease statistics, new issues, regulatory environment, laboratory regulation, reimbursement, payer types, and developments in personalized medicine. The clinical laboratory market is highly competitive in terms of prices, locations, and services offered. Larger laboratories have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. The report profiles companies that are the leaders in the industry, including: 3: Issues And Trends In The Clinical Laboratory Industry - Certificate of Compliance and Certificate of Accreditation - ALERE, Inc - Bio-Reference Laboratories - OPKO - Davita Healthcare Partners, Inc. - Genomic Health, Inc. - Genomic Health, Inc. - Laboratory Corporation of America - Myriad Genetics, Inc. - Neogenomics, Inc. - Quest Diagnostics, Inc. - Siemens Healthineers - Sonic Healthcare Limited - Spectra Laboratories: A Fresenius Company - Synlab International Gmbh For more information about this report visit http://www.researchandmarkets.com/research/m9hsjn/global_clinical Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-clinical-laboratory-market-analysis-2010-2021-market-leaders-are-quest-diagnostics-bio-reference-laboratories-opko-genomic-health-laboratory-corporation-of-america--myriad-genetics-300462442.html


A Liquid Biopsy, also known as Fluid Biopsy is the Sampling and Analysis of Non-Solid Biological Tissue, Primarily Blood. Like traditional biopsy this type of technique is mainly used as a Diagnostic and monitoring tool for diseases such as Cancer, with the added benefit of being largely non-invasive. With their unique quality of simplifying the Market Study Reports, “Market Research Future” presents a Brilliant study Report on the “Global Liquid Biopsy Market” Empowering you to browse through the full Market Analysis, Opportunities, Price, Growth, Trends and the market forecast up to the year 2022 Global Liquid Biopsy Market Report has been segmented on the basis of Therapeutic Area which comprises of Bladder cancer, Lung cancer, Brain cancer, Melanoma, Breast cancer, Non-Hodgkin lymphoma and others. On the basis of application the market is segmented into cancer Drug Development, Device Development, detection of Genetic Alterations in Tumors, cfDNA and others. On the basis of end user, market is segmented into Pharmaceutical Companies, Hospital/Clinics, Reference Laboratories, Research Institutes and others. Globally the market for Liquid Biopsy is expected to grow at a substantial rate during the period 2016 to 2022. Applications for Liquid Biopsy are expected to Witness Significant market development over the coming decade. Brain Cancer holds the largest share of the market. Some of the Key Players in this Market are: Myriad Genetics, F. Hoffmann-La Roche Ltd, QIAGEN, Biocept Inc., Trovagene, Inc, Genomic Health, RainDance Technologies, Inc, Bio-Rad Laboratories, Inc., Janssen Global Services, LLC, and others. The Report is advantageous mainly to the following Entities • Biotechnology Companies • Research Institutes • Research and Development (R&D) Companies • Liquid biopsy market service providers • Government Research Laboratories • Contract Research Organizations • Research and Consulting Companies • Liquid Biopsy Product Manufacturers and Distributors • Pharmaceutical Companies Access the market data and market information presented through more than 50 market data tables and 25 figures spread over 85 numbers of pages of the project report “Liquid biopsy Market –Forecast to 2022” Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America are the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster. • Provides detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the Liquid Biopsy Market • Offers insights about factors affecting the market growth • Enables to analyze the market based on various factors- Price Analysis, Supply Chain Analysis, Porters Five Force Analysis etc. • Provides historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa. • Offers country level analysis of the market with respect to the current market size and future prospective At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members. For more information, please visit https://www.marketresearchfuture.com

Loading Reference Laboratories collaborators
Loading Reference Laboratories collaborators